{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:13:00Z","timestamp":1793463180297,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2022LSW015"],"award-info":[{"award-number":["ZR2022LSW015"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023MB020"],"award-info":[{"award-number":["ZR2023MB020"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22477071"],"award-info":[{"award-number":["22477071"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","award":["2025SDUSKL23"],"award-info":[{"award-number":["2025SDUSKL23"]}],"id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmc.2026.118708","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:31:17Z","timestamp":1778945477000},"page":"118708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["SHP2-targeted cancer therapeutics: Structural insights, inhibitor development and emerging modalities"],"prefix":"10.1016","volume":"139","author":[{"given":"Yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengchun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojin","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118708_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/bs.acr.2023.03.003","article-title":"Setting sail: Maneuvering SHP2 activity and its effects in cancer","volume":"160","author":"Welsh","year":"2023","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.bmc.2026.118708_bb0010","article-title":"Tyrosine phosphatase PTPN11\/SHP2 in solid tumors - bull\u2019s eye for targeted therapy?","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.bmc.2026.118708_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225384","article-title":"Overcoming immune checkpoint therapy resistance with SHP2 inhibition in cancer and immune cells: a review of the literature and novel combinatorial approaches","volume":"15","author":"Tojjari","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118708_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107966","article-title":"Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials","volume":"230","author":"Song","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bmc.2026.118708_bb0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14728222.2022.2066518","article-title":"Targeting SHP2 phosphatase in hematological malignancies","volume":"26","author":"Kanumuri","year":"2022","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"10.1016\/j.bmc.2026.118708_bb0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13402-022-00698-1","article-title":"A comprehensive review of SHP2 and its role in cancer","volume":"45","author":"Asmamaw","year":"2022","journal-title":"Cell Oncol (Dordr)"},{"issue":"20","key":"10.1016\/j.bmc.2026.118708_bb0035","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in Cancer therapy: current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118708_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","article-title":"Allosteric SHP2 inhibitors in cancer: targeting the intersection of RAS, resistance, and the immune microenvironment","volume":"62","author":"Kerr","year":"2021","journal-title":"Curr Opin Chem Biol"},{"issue":"8","key":"10.1016\/j.bmc.2026.118708_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084468","article-title":"The discovery of potent SHP2 inhibitors with anti-proliferative activity in breast cancer cell lines","volume":"23","author":"Ghemrawi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.bmc.2026.118708_bb0050","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41417-022-00472-3","article-title":"Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K\/S6, Bim and Mcl-1","volume":"29","author":"Deng","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.bmc.2026.118708_bb0055","doi-asserted-by":"crossref","unstructured":"Chen YN, LaMarche MJ, Chan HM, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 2016;535(7610):148\u201352.","DOI":"10.1038\/nature18621"},{"issue":"1","key":"10.1016\/j.bmc.2026.118708_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"10.1016\/j.bmc.2026.118708_bb0065","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1021\/acs.jmedchem.1c02008","article-title":"Strategies targeting protein tyrosine phosphatase SHP2 for Cancer therapy","volume":"65","author":"Song","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118708_bb0070","doi-asserted-by":"crossref","unstructured":"LaMarche MJ, Acker M, Argintaru A, et al. Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer. J Med Chem 2020;63(22):13578\u201313594.","DOI":"10.1021\/acs.jmedchem.0c01170"},{"issue":"19","key":"10.1016\/j.bmc.2026.118708_bb0075","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.1021\/acs.jmedchem.3c00483","article-title":"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid Tumors","volume":"66","author":"Taylor","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118708_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113341","article-title":"Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders","volume":"218","author":"Yang","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"19","key":"10.1016\/j.bmc.2026.118708_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28196947","article-title":"Discovery of a SHP2 degrader with in vivo anti-tumor activity","volume":"28","author":"Miao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118708_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112657","article-title":"Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders","volume":"204","author":"Tang","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2026.118708_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073497","article-title":"Toward a treatment of cancer: design and in vitro\/in vivo evaluation of uncharged pyrazoline derivatives as a series of novel SHP2 inhibitors","volume":"23","author":"Dai","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.bmc.2026.118708_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168010","article-title":"Monobody inhibitor selective to the phosphatase domain of SHP2 and its use as a probe for quantifying SHP2 allosteric regulation","volume":"435","author":"Sha","year":"2023","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118708_bb0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41392-022-01038-3","article-title":"Targeting protein phosphatases for the treatment of inflammation-related diseases: from signaling to therapy","volume":"7","author":"Pan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2026.118708_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102722","article-title":"Cell phenotypes can be predicted from propensities of protein conformations","volume":"83","author":"Nussinov","year":"2023","journal-title":"Curr Opin Struct Biol"},{"issue":"11","key":"10.1016\/j.bmc.2026.118708_bb0115","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/2159-8290.CD-23-0383","article-title":"SHP2: a pleiotropic target at the Interface of Cancer and its microenvironment","volume":"13","author":"Sodir","year":"2023","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.bmc.2026.118708_bb0120","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/ddr.22100","article-title":"Allosteric modulation of SHP2: quest from known to unknown","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev Res"},{"issue":"5","key":"10.1016\/j.bmc.2026.118708_bb0125","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/med.21890","article-title":"Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery","volume":"42","author":"Song","year":"2022","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2026.118708_bb0130","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.csbj.2024.02.023","article-title":"Phosphopeptide binding to the N-SH2 domain of tyrosine phosphatase SHP2 correlates with the unzipping of its central \u03b2-sheet","volume":"23","author":"Marasco","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"issue":"2","key":"10.1016\/j.bmc.2026.118708_bb0135","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cell.2020.09.002","article-title":"Phase separation of disease-associated SHP2 mutants underlies MAPK hyperactivation","volume":"183","author":"Zhu","year":"2020","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.bmc.2026.118708_bb0140","article-title":"Synthetic lethality of SHP2 and XIAP suppresses proliferation and metastasis in KRAS-mutant nonsmall cell lung Cancer","volume":"12","author":"Fu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.bmc.2026.118708_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216517","article-title":"JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK\/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers","volume":"582","author":"Lu","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2026.118708_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115017","article-title":"Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects","volume":"247","author":"Lade","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118708_bb0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13058-022-01521-3","article-title":"Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors","volume":"24","author":"Heynen","year":"2022","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.bmc.2026.118708_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112117","article-title":"Therapeutic potential of targeting SHP2 in human developmental disorders and cancers","volume":"190","author":"Shen","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.bmc.2026.118708_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109974","article-title":"Single-cell transcriptomics reveals opposing roles of SHP2 in Myc-driven liver tumor cells and microenvironment","volume":"37","author":"Chen","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2026.118708_bb0170","article-title":"PKM2-driven metabolic reprogramming in digestive system tumors: mechanisms, therapeutic advances, and clinical challenges","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.bmc.2026.118708_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.527","article-title":"Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.bmc.2026.118708_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26697-8","article-title":"Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization","volume":"12","author":"Xu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118708_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104595","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118708_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40164-023-00379-1","article-title":"Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML","volume":"12","author":"Zhao","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10.1016\/j.bmc.2026.118708_bb0195","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1039\/D1MD00386K","article-title":"Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors","volume":"13","author":"Kong","year":"2022","journal-title":"RSC Med Chem"},{"issue":"6","key":"10.1016\/j.bmc.2026.118708_bb0200","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1021\/acs.jmedchem.3c02118","article-title":"Fragment-based discovery of allosteric inhibitors of SH2 domain-containing protein tyrosine Phosphatase-2 (SHP2)","volume":"67","author":"Day","year":"2024","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmc.2026.118708_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25116201","article-title":"Targeting SHP2 cryptic allosteric sites for effective cancer therapy","volume":"25","author":"Rehman","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.bmc.2026.118708_bb0210","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1124\/mol.106.025536","article-title":"Discovery of a novel SHP2 protein tyrosine phosphatase inhibitor","volume":"70","author":"Chen","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"20","key":"10.1016\/j.bmc.2026.118708_bb0215","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1073\/pnas.0710468105","article-title":"Specific inhibitors of the protein tyrosine phosphatase SHP2 identified by high-throughput docking","volume":"105","author":"Hellmuth","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.bmc.2026.118708_bb0220","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/cmdc.201500015","article-title":"Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo","volume":"10","author":"Grosskopf","year":"2015","journal-title":"ChemMedChem"},{"issue":"7","key":"10.1016\/j.bmc.2026.118708_bb0225","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1021\/acsmedchemlett.5b00118","article-title":"Exploring the existing drug space for novel pTyr mimetic and SHP2 inhibitors","volume":"6","author":"He","year":"2015","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"10.1016\/j.bmc.2026.118708_bb0230","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1021\/jm901645u","article-title":"Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)","volume":"53","author":"Zhang","year":"2010","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.bmc.2026.118708_bb0235","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1021\/jm5006176","article-title":"Therapeutic potential of targeting the oncogenic SHP2 phosphatase","volume":"57","author":"Zeng","year":"2014","journal-title":"J Med Chem"},{"issue":"23","key":"10.1016\/j.bmc.2026.118708_bb0240","doi-asserted-by":"crossref","first-page":"14780","DOI":"10.1021\/acs.jmedchem.0c01265","article-title":"From Pyrazolones to azaindoles: evolution of active-site SHP2 inhibitors based on scaffold hopping and bioisosteric replacement","volume":"63","author":"Mostinski","year":"2020","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2026.118708_bb0245","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2174\/1389557521666201222144355","article-title":"Approach in improving potency and selectivity of kinase inhibitors: allosteric kinase inhibitors","volume":"21","author":"Wei","year":"2021","journal-title":"Mini Rev Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2026.118708_bb0250","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1016\/j.apsb.2021.03.037","article-title":"Strategies to overcome drug resistance using SHP2 inhibitors","volume":"11","author":"Liu","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.bmc.2026.118708_bb0255","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/acschembio.7b00980","article-title":"Dual allosteric inhibition of SHP2 phosphatase","volume":"13","author":"Fodor","year":"2018","journal-title":"ACS Chem Biol"},{"issue":"2","key":"10.1016\/j.bmc.2026.118708_bb0260","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm Sin B"},{"issue":"16","key":"10.1016\/j.bmc.2026.118708_bb0265","doi-asserted-by":"crossref","first-page":"13534","DOI":"10.1021\/acs.jmedchem.4c00360","article-title":"Discovery of JAB-3312, a potent SHP2 allosteric inhibitor for cancer treatment","volume":"67","author":"Ma","year":"2024","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmc.2026.118708_bb0270","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1021\/acsmedchemlett.3c00059","article-title":"Discovery of a novel series of potent SHP2 allosteric inhibitors","volume":"14","author":"Petrocchi","year":"2023","journal-title":"ACS Med Chem Lett"},{"issue":"20","key":"10.1016\/j.bmc.2026.118708_bb0275","doi-asserted-by":"crossref","first-page":"15141","DOI":"10.1021\/acs.jmedchem.1c01132","article-title":"Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a potent and orally bioavailable SHP2 inhibitor","volume":"64","author":"Czako","year":"2021","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118708_bb0280","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/acs.jmedchem.8b01725","article-title":"Optimization of fused bicyclic allosteric SHP2 inhibitors","volume":"62","author":"Bagdanoff","year":"2019","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.bmc.2026.118708_bb0285","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-20-1634","article-title":"Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward Osimertinib","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.bmc.2026.118708_bb0290","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/acsmedchemlett.2c00454","article-title":"Discovery of a novel series of Imidazopyrazine derivatives as potent SHP2 allosteric inhibitors","volume":"14","author":"Torrente","year":"2023","journal-title":"ACS Med Chem Lett"},{"issue":"15","key":"10.1016\/j.bmc.2026.118708_bb0295","doi-asserted-by":"crossref","first-page":"13305","DOI":"10.1021\/acs.jmedchem.4c01217","article-title":"Design, synthesis and antitumor activity of a novel class of SHP2 allosteric inhibitors with a Furanyl amide-based scaffold","volume":"67","author":"Zhu","year":"2024","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2026.118708_bb0300","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1016\/j.apsb.2024.03.028","article-title":"Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor","volume":"14","author":"Tang","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"9","key":"10.1016\/j.bmc.2026.118708_bb0305","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.bmc.2026.118708_bb0310","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0959-8049(20)31089-3","article-title":"Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b\/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling","volume":"138","author":"Bendell","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.bmc.2026.118708_bb0315","article-title":"Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer","volume":"3","author":"Frank","year":"2022","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.bmc.2026.118708_bb0320","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/13543776.2024.2365410","article-title":"A patent review of SHP2 allosteric inhibitors (2018-present)","volume":"34","author":"Petrocchi","year":"2024","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"10.1016\/j.bmc.2026.118708_bb0325","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1080\/14756366.2021.1986491","article-title":"Design, synthesis, and biological evaluation of novel triazoloquinazolinone derivatives as SHP2 protein inhibitors","volume":"36","author":"Luo","year":"2021","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2026.118708_bb0330","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"14","key":"10.1016\/j.bmc.2026.118708_bb0335","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","volume":"63","author":"Wang","year":"2020","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmc.2026.118708_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.575","article-title":"PROteolysis-targeting chimeras (PROTACs) in leukemia: overview and future perspectives","volume":"5","author":"Vicente","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.bmc.2026.118708_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104788","article-title":"Novel PROTACs for degradation of SHP2 protein","volume":"110","author":"Zheng","year":"2021","journal-title":"Bioorg Chem"},{"issue":"34","key":"10.1016\/j.bmc.2026.118708_bb0350","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1021\/acs.biochem.1c00377","article-title":"Targeted degradation of the oncogenic phosphatase SHP2","volume":"60","author":"Vemulapalli","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2026.118708_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202405728","article-title":"Design, synthesis, and anticancer activity evaluation of the new SHP2 degraders","volume":"10","author":"Zhao","year":"2025","journal-title":"ChemistrySelect"},{"issue":"1","key":"10.1016\/j.bmc.2026.118708_bb0360","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2026.118708_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117918","article-title":"Discovery of SA-8 as a potent SHP2-AUTAC degrader in cancer therapy","volume":"297","author":"Song","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2026.118708_bb0370","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1021\/acs.jmedchem.4c02682","article-title":"Discovery of novel SHP2 ATTEC degraders against pancreatic ductal adenocarcinoma Harboring KRAS(G12D) mutations","volume":"68","author":"Zhong","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118708_bb0375","article-title":"PD-L1\/SHP2 dual protacs inhibit melanoma by enhancing t-cell killing activity","volume":"36","author":"Liu","year":"2025","journal-title":"Chin Chem Lett"},{"issue":"9","key":"10.1016\/j.bmc.2026.118708_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107616","article-title":"Bivalent target-binding bioprotacs induce potent degradation of oncogenic SHP2","volume":"300","author":"Hoffman","year":"2024","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.bmc.2026.118708_bb0385","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay4458","article-title":"Molecular mechanism of SHP2 activation by PD-1 stimulation","volume":"6","author":"Marasco","year":"2020","journal-title":"Sci Adv"},{"issue":"4","key":"10.1016\/j.bmc.2026.118708_bb0390","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s10753-021-01437-8","article-title":"SHP2 targets ITK downstream of PD-1 to inhibit T cell function","volume":"44","author":"Strazza","year":"2021","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.bmc.2026.118708_bb0395","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11427-024-2706-2","article-title":"Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP2","volume":"68","author":"Li","year":"2025","journal-title":"Sci China Life Sci"},{"issue":"6","key":"10.1016\/j.bmc.2026.118708_bb0400","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911571","article-title":"Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors","volume":"12","author":"Fan","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"21","key":"10.1016\/j.bmc.2026.118708_bb0405","doi-asserted-by":"crossref","first-page":"15973","DOI":"10.1021\/acs.jmedchem.1c01371","article-title":"Targeting oncogenic src homology 2 domain-containing phosphatase 2 (SHP2) by inhibiting its protein\u2013protein interactions","volume":"64","author":"Bobone","year":"2021","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118708_bb0410","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imm.13671","article-title":"6-mercaptopurine potently inhibits recruitment of SHP2 by phosphorylated PD-1 to inhibit PD-1 signalling and enhance t cell function","volume":"170","author":"Liu","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.bmc.2026.118708_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116579","article-title":"Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules","volume":"275","author":"Guo","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2026.118708_bb0420","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1021\/acs.jmedchem.2c00063","article-title":"Discovery of a novel src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) and cyclin-dependent kinase 4 (CDK4) dual inhibitor for the treatment of triple-negative breast cancer","volume":"65","author":"Chen","year":"2022","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.bmc.2026.118708_bb0425","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1021\/acs.jmedchem.2c00866","article-title":"Discovery of novel Src Homology-2 domain-containing phosphatase 2 and histone deacetylase dual inhibitors with potent antitumor efficacy and enhanced antitumor immunity","volume":"65","author":"Liu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118708_bb0430","series-title":"SHP2&NAMPT dual-targeting compound and its pharmaceutical composition and use. CN115521305. 2022-12-27","author":"Jiang","year":"2026"},{"key":"10.1016\/j.bmc.2026.118708_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117745","article-title":"Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer","volume":"294","author":"Zheng","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118708_bb0440","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1021\/acs.jmedchem.4c02760","article-title":"Covalent-allosteric inhibitors: do we get the best of both worlds?","volume":"68","author":"Tao","year":"2025","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118708_bb0445","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1021\/bi5013595","article-title":"Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase SHP2","volume":"54","author":"Chio","year":"2015","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.bmc.2026.118708_bb0450","doi-asserted-by":"crossref","first-page":"15763","DOI":"10.1021\/acsomega.8b02200","article-title":"The allosteric site on SHP2\u2019s protein tyrosine phosphatase domain is targetable with druglike small molecules","volume":"3","author":"Marsh-Armstrong","year":"2018","journal-title":"ACS Omega"},{"issue":"13","key":"10.1016\/j.bmc.2026.118708_bb0455","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj7251","article-title":"EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling","volume":"10","author":"Hu","year":"2024","journal-title":"Sci Adv"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:56:36Z","timestamp":1783144596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":91,"alternative-id":["S0968089626001641"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118708","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SHP2-targeted cancer therapeutics: Structural insights, inhibitor development and emerging modalities","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118708"}}